OPRM1 Asn40Asp predicts response to naltrexone treatment: A haplotype-based approach

Alcoholism: Clinical and Experimental Research

Volumn 33, Issue 3, 2009, Pages 383-393

  Oroszi, Gabor ^a   Anton, Raymond F ^a   O'Malley, Stephanie ^b   Swift, Robert ^c   Pettinati, Helen ^d   Couper, David ^e   Yuan, Qiaoping ^f   Goldman, David ^f  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f Laboratory of Neurogenetics   (United States)

Author keywords

Good Clinical Outcome; Haplotype; Haplotype by Medication Interaction; Naltrexone; OPRM1 Asn40Asp; Treatment Response

Indexed keywords

ACAMPROSATE; ASPARAGINE; ASPARTIC ACID; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO;

ABSTINENCE; ADULT; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFICACY; FEMALE; GENE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OPRM1 GENE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; ALCOHOLISM; AMINO ACID SUBSTITUTION; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME;

EID: 60649107477     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2008.00846.x     Document Type: Article

References (53)

1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 : 2003 2017.
2. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65 : 135 144.
3. Arias A, Feinn R, Kranzler HR (2006) Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 83 : 262 268.
4. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D (2005) Efficiency and power in genetic association studies. Nat Genet 37 : 1217 1223.
5. Bare LA, Mansson E, Yang D (1994) Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett 354 : 213 216.
6. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 : 263 265.
7. Bayerer B, Stamer U, Hoeft A, Stuber F (2007) Genomic variations and transcriptional regulation of the human mu-opioid receptor gene. Eur J Pain 11 : 421 427.
8. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276 : 3130 3137.
9. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL (2007) GenBank. Nucleic Acids Res 35 : D21 D25.
10. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D (1997) Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2 : 490 494.
11. Beyer A, Koch T, Schroder H, Schulz S, Hollt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89 : 553 560.
12. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95 : 9608 9613.
13. Borner C, Hollt V, Kraus J (2002) Involvement of activator protein-1 in transcriptional regulation of the human mu-opioid receptor gene. Mol Pharmacol 61 : 800 805.
14. Borner C, Kraus J, Schroder H, Ammer H, Hollt V (2004) Transcriptional regulation of the human mu-opioid receptor gene by interleukin-6. Mol Pharmacol 66 : 1719 1726.
15. Chong RY, Oswald L, Yang X, Uhart M, Lin PI, Wand GS (2006) The Micro-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 31 : 204 211.
16. Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria PA Jr., O'Brien CP, Berrettini WH, Grice DE (2003) A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 13 : 169 173.
17. Delfs JM, Kong H, Mestek A, Chen Y, Yu L, Reisine T, Chesselet MF (1994) Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level. J Comp Neurol 345 : 46 68.
18. den Dunnen JT, Antonarakis SE (2001) Nomenclature for the description of human sequence variations. Hum Genet 109 : 121 124.
19. Ehlers CL, Lind PA, Wilhelmsen KC (2008) Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. BMC Med Genet 9 (35).
20. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296 : 2225 2229.
21. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31 : 555 563.
22. Gelernter J, Kranzler H, Cubells J (1999) Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 4 : 476 483.
23. Gianoulakis C, Barcomb A (1987) Effect of acute ethanol in vivo and in vitro on the beta-endorphin system in the rat. Life Sci 40 : 19 28.
24. Goldman D, Oroszi G, O'Malley S, Anton R (2005) COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol Suppl 15 : 56 64. discussion 33.
25. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR (2003) Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 118B : 60 65.
26. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM (2000) Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 9 : 2895 2908.
27. Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I (2005) How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 26 : 311 317.
28. Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18 (Suppl. 4 S3 S13.
29. Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66 : 285 306.
30. Kraus J, Borner C, Giannini E, Hickfang K, Braun H, Mayer P, Hoehe MR, Ambrosch A, Konig W, Hollt V (2001) Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 276 : 43901 43908.
31. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 : 1734 1739.
32. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4 (3 184 192.
33. Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14 : 143 149.
34. Luo X, Kranzler HR, Zhao H, Gelernter J (2003) Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet 120 : 97 108.
35. Miller WR, Tonigan JS, Longabaugh R (1995) The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse (test manual). U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, DHHS Pub. No. 95-3911, Bethesda, MD.
36. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28 : 1546 1552.
37. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW (2005) Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 133 : 209 220.
38. Pasternak GW (2004) Multiple opiate receptors: deja vu all over again. Neuropharmacology 47 (Suppl 1 312 323.
39. Rommelspacher H, Smolka M, Schmidt LG, Samochowiec J, Hoehe MR (2001) Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol 24 : 129 135.
40. Shi MM, Myrand SP, Bleavins MR, de la Iglesia FA (1999) High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes. Mol Pathol 52 : 295 299.
41. Sobell MB, Schaefer HH, Mills KC (1972) Differences in baseline drinking behavior between alcoholics and normal drinkers. Behav Res Ther 10 : 257 267.
42. Sora I, Elmer G, Funada M, Pieper J, Li XF, Hall FS, Uhl GR (2001) Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 25 : 41 54.
43. Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73 : 1162 1169.
44. Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, Francis E, Hughes P, Duara R, Mullan M (1999) Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am J Med Genet 88 : 458 461.
45. Uhl GR, Sora I, Wang Z (1999) The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A 96 : 7752 7755.
46. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49 : 876 880.
47. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A (2002) The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26 : 106 114.
48. Xuei X, Flury-Wetherill L, Bierut L, Dick D, Nurnberger J Jr., Foroud T, Edenberg HJ (2007) The opioid system in alcohol and drug dependence: family-based association study. Am J Med Genet B Neuropsychiatr Genet 144 (7 877 884.
49. Zhang L, Kendler KS, Chen X (2006b) The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct 2 : 28.
50. Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, Zvartau E, Gelernter J (2006a) Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 15 : 807 819.
51. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280 : 32618 32624.
52. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, Virkkunen M, Mash DC, Lipsky RH, Hu XZ, Hodgkinson CA, Xu K, Buzas B, Yuan Q, Shen PH, Ferrell RE, Manuck SB, Brown SM, Hauger RL, Stohler CS, Zubieta JK, Goldman D (2008) Genetic variation in human NPY expression affects stress response and emotion. Nature 452 (7190 997 1001.
53. Zweben A, Cisler RA (2003) Clinical and methodological utility of a composite outcome measure for alcohol treatment research. Alcohol Clin Exp Res 27 : 1680 1685.